The US Food and Drug Administration (FDA) has issued a partial clinical hold on the enrolment of new patients in Epizyme’s ongoing Phase I and II trials of tazemetostat to treat genetically defined solid tumours and hematologic malignancies.

The clinical hold is based on a safety report submitted by Epizyme to the FDA, detailing the condition of a paediatric patient with advanced poorly differentiated chordoma who developed a secondary T-cell lymphoma in the Phase I trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

During the submission of the report, the patient had been on study for around 15 months and achieved a confirmed partial response.

"We are working expeditiously with clinical trial investigators and regulatory authorities to initiate the appropriate steps to resume enrolment."

Following the development of secondary malignancy, the patient has stopped taking tazemetostat and is currently being treated for T-cell lymphoma.

According to Epizyme, doses used in the Phase I trial are higher than the doses explored in the Phase II adult study, which is a very common approach used in the development of difficult-to-treat paediatric cancer drugs.

The company also noted that this is the only incident where a patient treated with tazemetostat developed secondary lymphoma under its clinical trial programme that has so far treated over 750 patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Epizyme president and CEO Robert Bazemore said: “Patient safety is of the utmost importance to Epizyme.

“We are working expeditiously with clinical trial investigators and regulatory authorities to initiate the appropriate steps to resume enrolment.

“Epizyme, along with our global investigator community, has been very encouraged by the clinical responses and tolerability of tazemetostat observed in paediatric and adult patients with hematological malignancies and solid tumours enrolled in our trials.”

Under the Phase I and II trials of tazemetostat, Epizyme aims to develop the EZH2 inhibitor as a monotherapy for the treatment of certain molecularly defined solid tumours, including epithelioid sarcoma and other INI1-negative tumours.